MARKET

ONCY

ONCY

Oncolytics Biotech Inc
NASDAQ
0.8740
-0.0131
-1.48%
After Hours: 0.9000 +0.026 +2.97% 19:11 12/31 EST
OPEN
0.8622
PREV CLOSE
0.8871
HIGH
0.8959
LOW
0.8622
VOLUME
676.52K
TURNOVER
--
52 WEEK HIGH
1.510
52 WEEK LOW
0.3258
MARKET CAP
94.05M
P/E (TTM)
-3.1015
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ONCY last week (1222-1226)?
Weekly Report · 12/29/2025 10:22
Weekly Report: what happened at ONCY last week (1215-1219)?
Weekly Report · 12/22/2025 10:22
Promising Potential of Oncolytics Biotech’s Pelareorep in KRAS-Mutant MSS Colorectal Cancer Drives Buy Rating
TipRanks · 12/17/2025 17:35
Lake Street Remains a Buy on Oncolytics Biotech (ONCY)
TipRanks · 12/17/2025 13:55
CANCER DRUG DEVELOPERS SECURE REGULATORY CLARITY AS FDA RESHAPES APPROVAL STANDARDS
Reuters · 12/16/2025 17:18
Oncolytics rises on additional data for pelareorep in colorectal cancer
Seeking Alpha · 12/16/2025 16:21
Oncolytics Biotech Reports Promising Pelareorep Data in Colorectal Cancer
TipRanks · 12/16/2025 14:38
Oncolytics reports clinical, translational findings from pelareorep development
TipRanks · 12/16/2025 14:20
More
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Webull offers Oncolytics Biotech Inc stock information, including NASDAQ: ONCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCY stock methods without spending real money on the virtual paper trading platform.